Monday, 3 July 2017

Miltenyi Cell Therapy Day at MHTP, 14 July

All staff and students are invited to the Miltenyi Biotec Australia Cell Therapy Day meeting at MHTP:

Friday July 14,  10:00 a.m. – 06:00 p.m.
Translational Research Facility, MHTP

Cell therapy has the potential to increase antitumor immunity, enhance vaccine efficacy, and limit graft-versus-host disease (GvHD).  At this Australia-first event, key opinion leaders from Australia and New Zealand will discuss and share newest information on adoptive immunotherapies and stem cell therapies, including gene manipulation. Participants are from all parts of Australia, including academic researcher and biotech industry, providing an ideal networking opportunity.

Please email or to register your attendance.  Limited places still available!

Program below:

10:00 a.m. – Welcome
Graham Jenkin, Monash Health Translation Precinct Cell Therapies Platform, Melbourne
Hermann Bohnenkamp, Miltenyi Biotec Pty Ltd., Sydney

10:10 a.m. Introduction
John Rasko, Royal Prince Alfred Hospital, Sydney

10:15 – 11:20 a.m. Session 1: Adoptive T cell therapies
Cell banks for therapy of viral and fungal infections: the case for depersonalised medicine
David Gottlieb, The Westmead Institute for Medical Research, Sydney
“Off-the-Shelf” Cellular immune therapies: Driving success with post-transplant lymphomas to infectious
complications and virus-associated cancers
Rajiv Khanna, QIMR Berghofer Medical Research Institute, Brisbane
Making immunotherapy simpler and cheaper to deliver using 3D lattices
Simon Barry, University of Adelaide, Adelaide
Morning tea

11:50 – 01:00 p.m. Session 2: Stem cell therapies
TCR α+β+/CD19+ cell depleted haploidentical donor stem cell transplantation for paediatric patients
Richard Mitchell, Sydney Children's Hospital, Sydney
Engraftment of gene-modified HSCs: One shot?
Geoff Symonds, Calimmune Pty Ltd., Sydney
Stem cells and gene editing in clinical medicine
Alan Trounson, Cartherics Pty Ltd., Melbourne

Lunch break

2:00 – 3:30 p.m. Session 3: Gene-modified T cell therapies
Improving T cell therapy with safety switch and gene marking
Siok Tey, QIMR Berghofer Medical Research Institute, Brisbane
Update on CARPETS Phase 1 Study of GD2-specific CAR T cell therapy for metastatic melanoma
Michael Brown, Centre for Cancer Biology, University of South Australia, Adelaide
New strategies for enhancing CAR T cell therapy for cancer
Phil Darcy, Peter MacCallum Cancer Centre, Melbourne
Transposon CAR T cells for Australia
Ken Micklethwaite, The Westmead Institute for Medical Research, Sydney

Afternoon Tea

4:00 – 4:30 p.m. Session 4: Technology update for cell manufacturing
Novel aspects of sorting in a closed System: Update on the MACSQuant® Tyto™
Jack Dunne, Owl Biomedical, Santa Barbara, CA, USA

5:00 p.m. Practical demonstration of the MACSQuant Tyto and the CliniMACS Prodigy®*
* To attend the demonstration, please register on-site.

No comments:

Post a Comment